Fibromyalgia is associated with altered brain function and emotion regulation difficulties. Alexithymia is common in fibromyalgia and may further affect emotion regulation in this population. This study examined the interplay of alexithymia and fibromyalgia on the brain function during suppression of negative emotions. Twenty-seven females with fibromyalgia and 30 controls performed an emotion regulation task while undergoing functional magnetic resonance imaging. Alexithymia was assessed using the Toronto Alexithymia Scale (TAS). A series of whole-brain multiple linear regressions was performed to estimate the effects of group, alexithymia and their interaction on activation and seed-based task-related functional connectivity. Reduced activation in the left middle frontal gyrus during negative emotion suppression, as well as reduced left amygdala–right temporo-parietal junction connectivity, increased left anterior insula-right posterior insula connectivity, and increased left anterior cingulate cortex-precuneus and inferior parietal lobule connectivity were evident in fibromyalgia. Increasing alexithymia was associated to stronger left anterior insula–inferior parietal lobule connectivity, across all groups. Following significant association between the group-by-TAS interaction and right amygdala–lingual gyri connectivity, moderation analysis indicated that increasing alexithymia was associated with reduced connectivity in healthy controls but not in fibromyalgia. This study highlights disrupted integration between emotional, interoceptive, and self-referential networks as a key feature of negative emotion suppression in fibromyalgia. Alexithymia moderates these disruptions by reducing emotional clarity and increasing internal focus. Interventions enhancing interoceptive awareness, fostering emotional understanding, and strengthening cognitive regulation may help normalise neural function and improve emotional functioning, especially in individuals with elevated alexithymia.

The authors have declared no competing interest.

This work was supported by a Rebecca Cooper Fellowship from the Rebecca L. Cooper Medical Research Foundation awarded to Sylvia M. Gustin.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used ONLY openly available human data that were originally located at https://openneuro.org/datasets/ds004144/versions/1.0.2

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes